about us
About Us
Technology platform
Technology Platform
YuceBio's Core Technology—Neoantigen Prediction

Neoantigen is a bridge that connects tumor genome and T cell immune response, and is the key to realizing the transformation of "diagnosis" and "treatment" products for tumor precision immunotherapy.

High-Quality Neoantigen Prediction Algorithm—TruNeo™
Analysis content involved in TruNeo™

Cross-validation of results by integrating multiple methods is unique to YuceBio

Test of missense antigen peptides
Exon test
MHCII affinity test
Test of splicing antigen peptides
Clonal prediction
Peptide homology prediction
Test of frameshift/non-frame shift indels antigen peptides
Calculation of expression abundance
Neoantigen database
Test of fusion gene antigen peptides
MHCI affinity prediction
Antigen scoring algorithm
Join TESLA to Jointly Establish an International Standard on Neoantigen Algorithm

The neoantigen test algorithm TruNeo™ is the only algorithm in China that has been validated by TESLA

TruNeo™ = Biology Deduction + Machine Learning + Experimental Validation

In common neoantigen algorithms, after the genomic mutations determined in each analysis stage have been screened, the number of peptides that are finally validated to be immunogenic is less than 10%. The TruNeo™ intelligent machine learning algorithm independently developed by YuceBio incorporates multiple factors in the biological pathways of neoantigen presentation and recognition, making the test of neoantigens more accurate. The neural network deep learning algorithm is also added for optimization. After years of efforts by TESLA and the Ladder for Cancer Moonshot Research Institute, YuceBio has an experimentally validated negative and positive neoantigen database and a shared neoantigen database, which can increase the number of peptides predicted.

High-Throughput Immunogenicity Double Validation Platform
EliSpot in vitro validation

Collect peripheral blood to validate the presence of neoantigen-specific T cells in PBMC.

NESt in vitro validation

High-throughput in vitro validation: Validate the immunogenicity of neoantigen, and obtain the sequence of the CDR3 region of TCR with affinity

In vivo validation in humanized PDTX mice

Used in preclinical study to evaluate the efficacy of personalized immunotherapy with tumor neoantigen

Neoantigen Database Dedicated to Personalized Immunotherapy
Database accumulation

Tumor cell line expression database: CCLE 1,000+

Chinese population HLA database: 20,000+

Cancer patient database: ICGC 1,000,000+/Chinese population 1,000+


High-frequency tumor neoantigen database

Protein MS data for colon cancer


Anchor residue database

MHC recognition/TAP transport/protease cleavage database


Neoantigen database derived from hematological tumor fusion genes

TESLA and own validation data

HPV virus neoantigen database


AI MS validation data

The Ladder for Cancer Moonshot database and other own databases

Algorithm upgrade

Relying on huge databases and a powerful bioinformatics technology and computing resource platform, the first Chinese prediction platform for all types of neoantigens (type I and type II MHC presentation, indels, and fusion-derived neoantigens) has been established.

Based on the TESLA validation data optimization algorithm, the algorithm accuracy has reached the world's leading level.

The functional modules are continuously optimized. Established the only system algorithm model that covers all biological aspects of the tumor neoantigen production process in China.

Established the first neoantigen algorithm model based on deep learning in China.

YuceBio Multi-Dimensional Tumor Immunoassay Platform
Gene sequencing platform
Expression analysis platform
NanoString nCounter® FLEX
Spatial expression analysis platform
NanoString GeoMx® Digital Spatial Profiler
Flow cytometry analysis platform
Agilent NovoCyte® Flow Cytometer
Pathology analysis platform
Leica Bond-RX Fully-Automated Slide Stainer
Akoya Vectra Polaris™ Fully-Automated Quantitative Pathology Imaging System
Dako Fully-Automated Immunohistochemical Staining System
nCounter Platform

Relying on the Central Lab service platform of YuceBio, many scientific researchers will be able to efficiently apply the nCounter technology and TIS (tumor inflammation signature) to a large number of clinical samples to conduct in-depth analysis on the complex tumor microenvironment and cell signaling pathways.

IO360 (Immnuno-Oncology 360)

Developed by NanoString, PanCancer IO 360™ gene expression panel can detect the expression of 770 genes and is for research use only (RUO). It combines important parts involved in the complex interaction between tumor, microenvironment, and cancer immune response to provide information on the characterization of various aspects of disease biology and the mechanism of immune escape.

More efficient: 770 genes and 18 immune signaling pathways

More precise: 48 biological signatures

Faster: Report in 24 h

TIS (Tumor Inflammation Signature)

Derived from the clinical data of Merck and validated in pan-cancer, TIS can predict the response to PD-1 antibody monotherapy K drug (Pembrolizumab) through the GEP data prediction of 18 genes.

It quantifies the strength of the peripherally suppressed adaptive immune response in the tumor microenvironment.

GeoMx™ DSP Platform

YuceBio can provide services related to in-situ expression analysis of multi-omics tissues with high-throughput, multi-omics, and flexible selection of regions.

GeoMx™ DSP is a brand new technology platform for space biology research released by NanoString. It can simultaneously achieve high parameters, multi-omics, and high precision while maintaining compatibility with paraffin samples (FFPE), fresh frozen samples, tissue microarrays, and other sample types. It can assay up to 96 proteins, 1833 RNA targets, or the whole transcriptome at one time in the same clinical sample, making it perfect for multi-omics study.

Multiplex IHC Platform
Akoya Biosciences
Multi-label staining

▪ Leica Bond-RX Fully-Automated Slide Stainer

▪ High stability without manual staining

▪ High repeatability with controllable program

Akoya Biosciences
Multi-label staining

▪ Multicolor immunohistochemistry and immunofluorescence

▪ Opal™ multi-labeling kit

▪ TSA Plus™ signal amplification

Automated sampling

▪ Specific tissue type and TMA tissue chip

▪ Vectra automated imaging

Intelligent analysis

▪ Artificial intelligence, machine learning

▪ InForm Tissue Finder™ software can be combined with the given examples for data optimization